His research group develops new platform technologies for cell and gene therapy; to this end, they converge knowledge and techniques of cell/gene/tissue engineering, drug delivery, biomaterials, micro/macro-fluidic bioreactors, transport phenomena, chemical kinetics, computational biology, and bioprocess engineering. He is the cofounder and director of Sentien Biotechnologies, Inc., and is affiliated with the Harvard Stem Cell Institute, the Broad Institute, and the American Society of Cell and Gene Therapy. He has received various honors and awards, including being named a 2016 finalist for the Translational Pioneer Award in Cell & Gene Therapy.